Jana Knop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jana Knop has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- A. Brandes
Takeda Pharma Vertrieb GmbH & Co. KG, Berlin, Germany
1 shared publication - Alisan Kahraman
Department of Gastroenterology and Hepatology, University Clinic of Essen, University of Duisburg-Essen, 45147 Essen, Germany
1 shared publication - Andreas Fuchs
AOK PLUS, Dresden, Germany
1 shared publication Andreas Stallmach
Department of Internal Medicine IV, Jena University Hospital , Jena , Germany
1 shared publication- Barthold Deiters
GWQ Serviceplus AG, Düsseldorf, Germany
1 shared publication - Bernd Bokemeyer
Clinic of General Internal Medicine I, University Hospital Schleswig‐Holstein Kiel Germany
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by eRelation AG in Monitor Versorgungsforschung
- Vol. 2026 (05) , 90-96
Kosten der ADHS-Versorgung in Deutschland: Analyse von GKV-Routinedaten der Jahre 2017 bis 2023
Einleitung: ADHS ist mit einer hohen Krankheitslast und erheblichen direkten sowie indirekten Kosten verbunden, insbesondere im Erwachsenenalter. Für Deutschland fehlen jedoch aktuelle gesundheitsökonomische Analysen mit langen Beobachtungszeiträumen. Methoden: Es wurde eine retrospektive Kohortenstudie auf Basis anonymisierter GKV-Routinedaten (InGef) von 2017 bis 2023 durchgeführt. Die Analyse umfasst prävalente und inzidente ADHS-Patient:innen (<18/≥18 Jahre) mit Fokus auf nicht-medikamentöse Versorgung, direkte Kosten und Arbeitsunfähigkeit. Ergebnisse: 2023 betrugen die durchschnittlichen direkten Gesamtkosten 3.527 Euro (prävalent) bzw. 4.250 Euro (inzident) pro Patient und waren bei Erwachsenen deutlich höher als bei Kindern/Jugendlichen. Stationäre Leistungen stellten den größten Kostenanteil dar. 14 bis 17 % der Patient:innen nutzten Psychotherapie. 8–10% der Patient:innen nutzten Verhaltenstherapie, mit durchschnittlich ~14 Sitzungen/Jahr und Kosten von ~1.5 Tsd. Euro/Patient:in/Jahr. Von 2017 bis 2023 stiegen die direkten Kosten um 43–46%. Der Anteil Erwachsener mit Arbeitsunfähigkeit und deren Dauer nahmen insbesondere ab 2021 deutlich zu. Diskussion: Die ADHS-Versorgung in Deutschland ist mit steigenden Kosten verbunden, die vor allem durch stationäre Behandlungen und psychotherapeutische Interventionen geprägt sind. Eine frühzeitige, kontinuierliche und ambulant-multimodale Versorgung könnte kostenintensive stationäre Leistungen und Produktivitätsverluste reduzieren.
- 5 October 2026
- Published by eRelation AG in Monitor Versorgungsforschung
- Vol. 2026 (05) , 90-96
Open AccessKosten der ADHS-Versorgung in Deutschland: Analyse von GKV-Routinedaten der Jahre 2017 bis 2023
Einleitung: ADHS ist mit einer hohen Krankheitslast und erheblichen direkten sowie indirekten Kosten verbunden, insbesondere im Erwachsenenalter. Für Deutschland fehlen jedoch aktuelle gesundheitsökonomische Analysen mit langen Beobachtungszeiträumen. Methoden: Es wurde eine retrospektive Kohortenstudie auf Basis anonymisierter GKV-Routinedaten (InGef) von 2017 bis 2023 durchgeführt. Die Analyse umfasst prävalente und inzidente ADHS-Patient:innen (<18/≥18 Jahre) mit Fokus auf nicht-medikamentöse Versorgung, direkte Kosten und Arbeitsunfähigkeit. Ergebnisse: 2023 betrugen die durchschnittlichen direkten Gesamtkosten 3.527 Euro (prävalent) bzw. 4.250 Euro (inzident) pro Patient und waren bei Erwachsenen deutlich höher als bei Kindern/Jugendlichen. Stationäre Leistungen stellten den größten Kostenanteil dar. 14 bis 17 % der Patient:innen nutzten Psychotherapie. 8–10% der Patient:innen nutzten Verhaltenstherapie, mit durchschnittlich ~14 Sitzungen/Jahr und Kosten von ~1.5 Tsd. Euro/Patient:in/Jahr. Von 2017 bis 2023 stiegen die direkten Kosten um 43–46%. Der Anteil Erwachsener mit Arbeitsunfähigkeit und deren Dauer nahmen insbesondere ab 2021 deutlich zu. Diskussion: Die ADHS-Versorgung in Deutschland ist mit steigenden Kosten verbunden, die vor allem durch stationäre Behandlungen und psychotherapeutische Interventionen geprägt sind. Eine frühzeitige, kontinuierliche und ambulant-multimodale Versorgung könnte kostenintensive stationäre Leistungen und Produktivitätsverluste reduzieren.
- Open Access
- 22 May 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (7) , 3419-3436
Patient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study
Introduction Management of cytomegalovirus (CMV) viremia/disease in transplant recipients may be complicated by toxicities and resistance to conventional antivirals, adding to the overall healthcare burden. Despite advances in analyzing real-world data in current years, little is known about refractory and resistant CMV. This study therefore aimed to characterize treatment patterns and patient numbers with special focus on refractory and resistant CMV. Methods Two classical three-round Delphi consensus panels with German clinical experts in CMV following solid organ transplantations (SOT) and hematopoietic stem cell transplantations (HSCT) were held between October and December 2021 using online questionnaires. Consensus was defined as agreement of 75% of participants. Results Following SOT, experts agreed that on average 65% of SOT patients are not affected by CMV at all, while 35% of patients experience CMV viremia or disease. Of SOT patients treated with antiviral therapies, experts agreed that 90% respond to their first-line treatment and 10% do not. For HSCT, experts agreed that 62% of patients experience no CMV, while 38% of patients are diagnosed with either CMV viremia or CMV disease. It was further estimated that 23% HSCT patients receiving antiviral treatment do not respond to their first-line CMV treatment. Experts reached consensus on the reasons for non-response, suggesting that among non-responders, 55% were intolerant, while 45% of non-responders were refractory/resistant to first-line treatment. Conclusion Based on the current incidence of transplantations in Germany, experts estimated that 103 SOT and 225 HSCT patients need second-line CMV treatment annually.
- 22 May 2025
- Published by Springer Nature in Advances in Therapy
- Vol. 42 (7) , 3419-3436
Open AccessPatient Number and Treatment Patterns in Cytomegalovirus Viremia and Disease Following Solid Organ and Hematopoietic Stem Cell Transplantation in Germany: Results of a Delphi Consensus Study
Introduction Management of cytomegalovirus (CMV) viremia/disease in transplant recipients may be complicated by toxicities and resistance to conventional antivirals, adding to the overall healthcare burden. Despite advances in analyzing real-world data in current years, little is known about refractory and resistant CMV. This study therefore aimed to characterize treatment patterns and patient numbers with special focus on refractory and resistant CMV. Methods Two classical three-round Delphi consensus panels with German clinical experts in CMV following solid organ transplantations (SOT) and hematopoietic stem cell transplantations (HSCT) were held between October and December 2021 using online questionnaires. Consensus was defined as agreement of 75% of participants. Results Following SOT, experts agreed that on average 65% of SOT patients are not affected by CMV at all, while 35% of patients experience CMV viremia or disease. Of SOT patients treated with antiviral therapies, experts agreed that 90% respond to their first-line treatment and 10% do not. For HSCT, experts agreed that 62% of patients experience no CMV, while 38% of patients are diagnosed with either CMV viremia or CMV disease. It was further estimated that 23% HSCT patients receiving antiviral treatment do not respond to their first-line CMV treatment. Experts reached consensus on the reasons for non-response, suggesting that among non-responders, 55% were intolerant, while 45% of non-responders were refractory/resistant to first-line treatment. Conclusion Based on the current incidence of transplantations in Germany, experts estimated that 103 SOT and 225 HSCT patients need second-line CMV treatment annually.
- Open Access
- 28 May 2022
- Published by Springer Nature in Infection
- Vol. 50 (6) , 1543-1555
Cytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data
Purpose: This study aimed to describe the cytomegalovirus (CMV) infection rate, rehospitalizations, and comorbidities following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantation (SOT). Methods: Patients who received allo-HSCT or SOT in 01/07/2015–30/06/2018 were identified using anonymized German claims data. The transplantation-related hospital admission date was defined as the index date, and patients were followed for up to 12 months (or death, first event relevant). The frequency of CMV infections (confirmed outpatient/inpatient diagnoses, ICD-10-GM codes: B25.-/B27.1) and the rate, number, and duration of all-cause rehospitalizations in the follow-up period were evaluated. Results: A total of 226 allo-HSCT and 250 SOT patients were identified (mean age 52.8 years, 38.9% female). During the 12 months after transplantation, 29.2% of allo-HSCT patients and 16.8% of SOT patients received a CMV diagnosis. The majority of these diagnoses were given during the initial hospitalization or within the following 3 months. Across transplantation types, CMV patients had more hospital readmission days per patient-year (allo-HSCT 93.3 vs. 49.4, p = 0.001; SOT 42.0 vs. 20.7, p = 0.005), with a longer mean duration of readmissions (allo-HSCT 22.4 vs. 15.4 days, p < 0.001; SOT 11.6 vs. 7.5 days, p = 0.003). Comorbidity burden in transplantation patients was substantial, with several diagnoses being significantly more common among patients with CMV vs. non-CMV. One-year mortality did not differ significantly between patients with/without CMV. Conclusion: Burden of transplant recipients with CMV in terms of rehospitalizations and comorbidities is substantial, highlighting the need for improved CMV prevention and treatment.
- 28 May 2022
- Published by Springer Nature in Infection
- Vol. 50 (6) , 1543-1555
Open AccessCytomegalovirus infection and rehospitalization rates after allogeneic hematopoietic stem cell and solid organ transplantation: a retrospective cohort study using German claims data
Purpose: This study aimed to describe the cytomegalovirus (CMV) infection rate, rehospitalizations, and comorbidities following allogeneic hematopoietic stem cell transplantation (allo-HSCT) and solid organ transplantation (SOT). Methods: Patients who received allo-HSCT or SOT in 01/07/2015–30/06/2018 were identified using anonymized German claims data. The transplantation-related hospital admission date was defined as the index date, and patients were followed for up to 12 months (or death, first event relevant). The frequency of CMV infections (confirmed outpatient/inpatient diagnoses, ICD-10-GM codes: B25.-/B27.1) and the rate, number, and duration of all-cause rehospitalizations in the follow-up period were evaluated. Results: A total of 226 allo-HSCT and 250 SOT patients were identified (mean age 52.8 years, 38.9% female). During the 12 months after transplantation, 29.2% of allo-HSCT patients and 16.8% of SOT patients received a CMV diagnosis. The majority of these diagnoses were given during the initial hospitalization or within the following 3 months. Across transplantation types, CMV patients had more hospital readmission days per patient-year (allo-HSCT 93.3 vs. 49.4, p = 0.001; SOT 42.0 vs. 20.7, p = 0.005), with a longer mean duration of readmissions (allo-HSCT 22.4 vs. 15.4 days, p < 0.001; SOT 11.6 vs. 7.5 days, p = 0.003). Comorbidity burden in transplantation patients was substantial, with several diagnoses being significantly more common among patients with CMV vs. non-CMV. One-year mortality did not differ significantly between patients with/without CMV. Conclusion: Burden of transplant recipients with CMV in terms of rehospitalizations and comorbidities is substantial, highlighting the need for improved CMV prevention and treatment.
- 1 August 2021
- Published by Georg Thieme Verlag KG
- Vol. 59 (08) , A 056
Die Patientenperspektive in der Behandlung von Morbus Crohn: Ein Discrete Choice Experiment zur Erhebung von Therapiepräferenzen in Deutschland
Einleitung Verschiedene Behandlungsoptionen für Patienten mit Morbus Crohn (MC), die auf konventionelle Therapien nicht ausreichend ansprechen, wurden in den letzten Jahren entwickelt. Allerdings ist noch wenig über die Präferenzen der Patienten hierzu bekannt. Ziele Diese multizentrische Querschnittsbefragung zielte darauf ab, die Präferenzen von Patienten in Bezug auf unterschiedliche Biologika zur Behandlung von MC in Deutschland zu ermitteln. Methodik Auf Basis einer qualitativen Vorstudie wurde ein Discrete Choice Experiment (DCE) entwickelt. Nachfolgend wurden gastroenterologisch behandelte Patienten mit MC > 18 Jahre in eine deutschlandweite quantitative Befragung eingeschlossen. Im Rahmen von Telefoninterviews entschieden sich die Patienten in insgesamt 8 unterschiedlichen Auswahlsituationen zwischen jeweils zwei hypothetischen Therapieoptionen. Die relativen Wichtigkeiten der untersuchten Therapieeigenschaften wurden aus den Koeffizienten eines konditionalen Logit-Models abgeleitet. Ergebnis Insgesamt wurden 118 Patienten (56,8 % weiblich; Durchschnittsalter: 39,6 Jahre; 87,3 % Biologika-erfahren) befragt. Von den im DCE berücksichtigten Eigenschaften war die Remissionsrate nach 1 Jahr am wichtigsten für die Therapieentscheidung (42,3 % der Gesamtentscheidung). Am zweitwichtigsten war die Auftrittswahrscheinlichkeit schwerwiegender unerwünschter Ereignisse (UE) im ersten Jahr der Behandlung (25,1 %), gefolgt von der Wahrscheinlichkeit einer Remissionshaltung über 2 Jahre (17,8 %). Die geringste Bedeutung wurde der Art der Verabreichung (14,6 %) und den nicht-schwerwiegenden UE (0,1 %) zugewiesen. Zudem ordneten Patienten einer 4-12 wöchentlichen (w.) subkutanen Anwendung und einer 4-8 w. intravenösen Gabe einen ähnlich hohen Nutzen zu, während eine 1-2 w. subkutane Injektion als klar unterlegen bewertet wurde. Schlussfolgerung Unser DCE liefert neue Einblicke in die Therapiepräferenzen von MC Patienten und zeigt, dass diese Patienten Behandlungsoptionen bevorzugen, die eine hohe Ansprechrate und eine geringere Wahrscheinlichkeit schwerer UEs bieten. Obwohl die Art der Verabreichung nur eine untergeordnete Rolle spielt, gibt es unabhängig von der Darreichungsform eine Präferenz für längere Behandlungsintervalle. Publication Date: 07 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 August 2021
- Published by Georg Thieme Verlag KG
- Vol. 59 (08) , A 056
Die Patientenperspektive in der Behandlung von Morbus Crohn: Ein Discrete Choice Experiment zur Erhebung von Therapiepräferenzen in Deutschland
Einleitung Verschiedene Behandlungsoptionen für Patienten mit Morbus Crohn (MC), die auf konventionelle Therapien nicht ausreichend ansprechen, wurden in den letzten Jahren entwickelt. Allerdings ist noch wenig über die Präferenzen der Patienten hierzu bekannt. Ziele Diese multizentrische Querschnittsbefragung zielte darauf ab, die Präferenzen von Patienten in Bezug auf unterschiedliche Biologika zur Behandlung von MC in Deutschland zu ermitteln. Methodik Auf Basis einer qualitativen Vorstudie wurde ein Discrete Choice Experiment (DCE) entwickelt. Nachfolgend wurden gastroenterologisch behandelte Patienten mit MC > 18 Jahre in eine deutschlandweite quantitative Befragung eingeschlossen. Im Rahmen von Telefoninterviews entschieden sich die Patienten in insgesamt 8 unterschiedlichen Auswahlsituationen zwischen jeweils zwei hypothetischen Therapieoptionen. Die relativen Wichtigkeiten der untersuchten Therapieeigenschaften wurden aus den Koeffizienten eines konditionalen Logit-Models abgeleitet. Ergebnis Insgesamt wurden 118 Patienten (56,8 % weiblich; Durchschnittsalter: 39,6 Jahre; 87,3 % Biologika-erfahren) befragt. Von den im DCE berücksichtigten Eigenschaften war die Remissionsrate nach 1 Jahr am wichtigsten für die Therapieentscheidung (42,3 % der Gesamtentscheidung). Am zweitwichtigsten war die Auftrittswahrscheinlichkeit schwerwiegender unerwünschter Ereignisse (UE) im ersten Jahr der Behandlung (25,1 %), gefolgt von der Wahrscheinlichkeit einer Remissionshaltung über 2 Jahre (17,8 %). Die geringste Bedeutung wurde der Art der Verabreichung (14,6 %) und den nicht-schwerwiegenden UE (0,1 %) zugewiesen. Zudem ordneten Patienten einer 4-12 wöchentlichen (w.) subkutanen Anwendung und einer 4-8 w. intravenösen Gabe einen ähnlich hohen Nutzen zu, während eine 1-2 w. subkutane Injektion als klar unterlegen bewertet wurde. Schlussfolgerung Unser DCE liefert neue Einblicke in die Therapiepräferenzen von MC Patienten und zeigt, dass diese Patienten Behandlungsoptionen bevorzugen, die eine hohe Ansprechrate und eine geringere Wahrscheinlichkeit schwerer UEs bieten. Obwohl die Art der Verabreichung nur eine untergeordnete Rolle spielt, gibt es unabhängig von der Darreichungsform eine Präferenz für längere Behandlungsintervalle. Publication Date: 07 September 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 July 2021
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 3 (3) , otab050
Novel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases—LISTEN 1
Background: Several patient-reported outcomes (PROs) have been established and are widely used in the assessment of patients with inflammatory bowel disease (IBD). However, it has never been investigated which PRO items are experienced by and are considered most relevant for IBD patients. Methods: A review of IBD-related disease scores by a steering committee led to the identification of relevant PRO questions and assignment to 16 different PRO categories (9 symptoms and 7 impacts) that characterize patient’s disease burden. In a cross-sectional study, a digital patient survey was carried out to determine the self-reported experience by multiple response, the relevance of these PRO categories by pairwise comparison and the suitability of the respective questions and answer possibilities by yes-or-no-question. Results: Sixty patients with Crohn’s disease (CD) (56.7% women; mean age 40.6 years; mean disease duration 12.4 years) and 60 patients with ulcerative colitis (UC) (51.7% women; mean age 37.3 years; mean disease duration 9.0 years) participated in the patient survey. All predefined symptoms and impacts, with the exception of nausea, were experienced by at least 50% of patients. Stool urgency and pain were rated the 2 most important symptoms in CD patients with similar ratings for relevance. Stool urgency was also the most important symptom in patients with UC, followed by stool frequency. Differences in self-reported experience between CD and UC patients were seen for the symptoms of rectal bleeding, pain, and nausea. Most important impact of symptoms in both patient groups were general wellbeing followed by social activities, while sexual activity was the least relevant impact category. Conclusions: Stool urgency was the most relevant and most self-reported symptom for both CD and UC. Relevance and self-reported experience of pain and rectal bleeding differed between the 2 diseases. Therefore, the future collection of PROs should take these disease specificities into consideration.
- 1 July 2021
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 3 (3) , otab050
Open AccessNovel Approaches Identifying Relevant Patient-Reported Outcomes in Patients With Inflammatory Bowel Diseases—LISTEN 1
Background: Several patient-reported outcomes (PROs) have been established and are widely used in the assessment of patients with inflammatory bowel disease (IBD). However, it has never been investigated which PRO items are experienced by and are considered most relevant for IBD patients. Methods: A review of IBD-related disease scores by a steering committee led to the identification of relevant PRO questions and assignment to 16 different PRO categories (9 symptoms and 7 impacts) that characterize patient’s disease burden. In a cross-sectional study, a digital patient survey was carried out to determine the self-reported experience by multiple response, the relevance of these PRO categories by pairwise comparison and the suitability of the respective questions and answer possibilities by yes-or-no-question. Results: Sixty patients with Crohn’s disease (CD) (56.7% women; mean age 40.6 years; mean disease duration 12.4 years) and 60 patients with ulcerative colitis (UC) (51.7% women; mean age 37.3 years; mean disease duration 9.0 years) participated in the patient survey. All predefined symptoms and impacts, with the exception of nausea, were experienced by at least 50% of patients. Stool urgency and pain were rated the 2 most important symptoms in CD patients with similar ratings for relevance. Stool urgency was also the most important symptom in patients with UC, followed by stool frequency. Differences in self-reported experience between CD and UC patients were seen for the symptoms of rectal bleeding, pain, and nausea. Most important impact of symptoms in both patient groups were general wellbeing followed by social activities, while sexual activity was the least relevant impact category. Conclusions: Stool urgency was the most relevant and most self-reported symptom for both CD and UC. Relevance and self-reported experience of pain and rectal bleeding differed between the 2 diseases. Therefore, the future collection of PROs should take these disease specificities into consideration.
- Open Access
- 18 May 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 35 (8) , 1587-1598
Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting
Background and aims: While a minority of inflammatory bowel disease (IBD) patients receives biologics in Germany, little is known about therapeutic needs of patients receiving non-biologic therapies. This study aimed to identify indicators of active disease/steroid dependency in patients with moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) treated with conventional therapies and to describe health care resource use (HCRU)/cost. Methods: CD/UC patients treated with immunosuppressants (IS) and/or systemic or locally acting oral corticosteroids (CS) were identified in German claims data (2013–2017) and followed for 12 months post-therapy start. Indicators of active disease/steroid dependency during follow-up period were (i) ≥ 2 prescriptions of CS (sensitivity ≥ 4) or (ii) ≥ 1 IBD-related surgery or (iii) > 7 days IBD-related hospitalization(s). Results: Of 9871 included IBD patients (5170 CD, 4701 UC), 25.7%/19.9% (CD/UC) received ≥ 2 prescriptions of CS (sensitivity, 17.4%/15.7%) (i), 3.2% experienced IBD-related surgeries (ii), and 2.5% > 7 days of hospitalizations (iii). Altogether, 44.4% had indicators of active disease/steroid dependency (sensitivity, 23.9%). Among patients with active disease/steroid dependency, 78.0% received CS monotherapy at baseline. Of these, 89.6% received a CS monotherapy in the follow-up period, too. Proportionally, fewer patients with CS monotherapy (57.4%) than IS therapy (91.0%) visited a specialist. HCRU/cost per patient year was significantly higher in patients with than without active disease/steroid dependency. Conclusions: A substantial percentage of biologic-naïve IBD patients suffers from active disease/steroid dependency. The majority receives a monotherapy with systemic CS. Referral to gastroenterologists for treatment optimization is recommended, also because active disease/steroid dependency is associated with increased HCRU/cost.
- 18 May 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 35 (8) , 1587-1598
Open AccessIndicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-setting
Background and aims: While a minority of inflammatory bowel disease (IBD) patients receives biologics in Germany, little is known about therapeutic needs of patients receiving non-biologic therapies. This study aimed to identify indicators of active disease/steroid dependency in patients with moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC) treated with conventional therapies and to describe health care resource use (HCRU)/cost. Methods: CD/UC patients treated with immunosuppressants (IS) and/or systemic or locally acting oral corticosteroids (CS) were identified in German claims data (2013–2017) and followed for 12 months post-therapy start. Indicators of active disease/steroid dependency during follow-up period were (i) ≥ 2 prescriptions of CS (sensitivity ≥ 4) or (ii) ≥ 1 IBD-related surgery or (iii) > 7 days IBD-related hospitalization(s). Results: Of 9871 included IBD patients (5170 CD, 4701 UC), 25.7%/19.9% (CD/UC) received ≥ 2 prescriptions of CS (sensitivity, 17.4%/15.7%) (i), 3.2% experienced IBD-related surgeries (ii), and 2.5% > 7 days of hospitalizations (iii). Altogether, 44.4% had indicators of active disease/steroid dependency (sensitivity, 23.9%). Among patients with active disease/steroid dependency, 78.0% received CS monotherapy at baseline. Of these, 89.6% received a CS monotherapy in the follow-up period, too. Proportionally, fewer patients with CS monotherapy (57.4%) than IS therapy (91.0%) visited a specialist. HCRU/cost per patient year was significantly higher in patients with than without active disease/steroid dependency. Conclusions: A substantial percentage of biologic-naïve IBD patients suffers from active disease/steroid dependency. The majority receives a monotherapy with systemic CS. Referral to gastroenterologists for treatment optimization is recommended, also because active disease/steroid dependency is associated with increased HCRU/cost.